Tempus, the medical technology company founded and run by the billionaire behind the digital coupon site Groupon, announced this morning that it is launching a new service that will use artificial intelligence to get more patients into clinical trials for cancer.

Eric Lefkofsky, the founder and chief executive of Tempus, started the company after being shocked at the disorganization of the medical system when his wife developed breast cancer. (He’s said she’s doing well.) His past success and the scale of his vision — combining genomics, AI, and collaboration with top cancer centers — has allowed him to raise a startling amount of money. Last week, Tempus raised $200 million from investors including Baillie Gifford, Franklin Templeton Investments, and New Enterprise Associates, bringing the total amount the company has raised to $520 million and valuing Tempus at $3.1 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy